Prostatic CancerPhase 2NCT06836271
Cleaning the Biopsy Needle in TRUS Bx
A Phase 2 study testing Isopropyl Alcohol, Povidine-iodine and formaldehit in people with Prostatic Cancer, run by Hitit University.
Trial summary
Prostate cancer(PCa) is the second most common cancer diagnosed in men. Clinical suspicion of PCa is mentioned in patients with digital rectal examination findings and elevated serum PSA. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Prostatic Cancer
- What is being tested?
- Isopropyl Alcohol, Povidine-iodine and formaldehit
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- 1 Mar 2025to 30 Jun 2025
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Oriented-coopere patients
- Patients without active urinary tract infection - Patients without active urinary tract infection
- Patients without bleeding diathesis
- Patients who accept the study
Who cannot join
- Patients with active urinary tract infection
- Patients with bleeding diathesis
- Patients with sonal or cystofix
- Patients with a history of previous prostate surgery
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: The Effect of Cleaning the Biopsy Needle With Isopropyl Alcohol, Povidone Iodine and Formalin Before Transrectal Ultrasonography-guided Prostate Biopsy on Procedure-related Infective Complications
Prostate cancer(PCa) is the second most common cancer diagnosed in men. Clinical suspicion of PCa is mentioned in patients with digital rectal examination findings and elevated serum PSA. Despite all the advances in radiological imaging methods, the gold standard method in the diagnosis of the disease is systematic prostate biopsy performed under the guidance of transrectal ultrasonography, which is an invasive procedure.
In TRUS-guided transrectal prostate biopsy, bacteriuria may develop as a result of the rectum flora being injected into the urinary system through a biopsy needle. Infective complications may be encountered as a result of this contamination. Infective complications can present with conditions ranging from asymptomatic bacteriuria to sepsis.
Read more
A study has shown that disinfection of the biopsy needle with isopropyl alcohol reduces sepsis due to prostate biopsy compared to the standard procedure. In another study, disinfection of the biopsy needle tip with formalin was found to be associated with a decrease in infectious complications after transrectal prostate biopsy.
In this study, investigators aimed to conduct a prospective study comparing Transrectal Ultrasonography-guided Prostate Biopsy cases, in which the biopsy needle was cleaned with isopropyl alcohol, povidone iodine and formalin, and standard biopsy patients in terms of infectious complications.
Read the detailed description
Objective To reduce procedure-related infective complications after Transrectal Ultrasonography-guided Prostate Biopsy Method Prostate cancer is the second most common cancer diagnosed in men. In 2020, approximately 1.4 million people were diagnosed worldwide [1,2]. The number of PCa detected by autopsy is roughly the same worldwide [3]. In a systematic review of autopsy studies, the prevalence of PCa under the age of 30 years was reported to be 5% (confidence interval-CI: 95%), with a 1.7 (1.6-1.8) (odds ratio-OR) fold increase per 10 years, reaching 59% (48-71%) over the age of 79 years [4].
Clinical suspicion of PCa is mentioned in patients with finger rectal examination findings and elevated serum PSA. Despite all the advances in radiologic imaging modalities, the gold standard method for the diagnosis of the disease is systematic prostate biopsy under transrectal ultrasonography guidance, which is an invasive procedure. [5]
Transrectal ultrasonography (TRUS) was first described by Wild and Reid in 1957. TRUS plays an important role in prostate diseases as it is inexpensive, easily applicable and guides biopsy. Conventional TRUS-guided prostate biopsy is performed with 12 pieces of tru-cut samples taken systematically and randomized.
Although it can be safely performed in the outpatient setting and is easily tolerated by patients, Transrectal Ultrasonography-guided Prostate Biopsy can lead to serious complications such as hematuria, rectal bleeding, acute urinary retention, urinary tract infection and sepsis.
Urinary tract infection accompanied by fever is the most common complication after biopsy. Bacteriuria after prostate biopsy is reported between 20% and 50% in the literature. [6] Several studies have shown that antibiotic prophylaxis largely prevents infection. [6,7]
During TRUS-guided transrectal prostate biopsy, bacteriuria may develop as a result of the rectal flora being introduced into the urinary system through the biopsy needle. Infective complications may occur as a result of this transmission. Infective complications can range from asymptomatic bacteriuria to sepsis.
In one study, disinfection of the biopsy needle with isopropyl alcohol was shown to reduce prostate biopsy-related sepsis compared to the standard procedure. [8] In another study, disinfection of the biopsy needle tip with formalin was associated with a decrease in infectious complications after transrectal prostate biopsy.[9] In this study, investigators aimed to prospectively examine the infectious complications occurring in a total of 200 cases of Transrectal Ultrasonography-guided Prostate Biopsy to be performed in our clinic in 2025.
In 200 patients who underwent Trans Rectal Ultrasonography-guided prostate biopsy procedure, infective parameters, signs and symptoms such as fever, dysuria, and possible complications such as hospitalization requirement, sepsis will be prospectively investigated to evaluate postop infective complications of disinfection of the biopsy needle with formalin, povidone iodine or isopropyl alcohol before each biopsy.
In the study, each patient will undergo bt-enema for bowel cleansing before the procedure, rectal cleansing with povidone iodine, and prophylactic antibiotherapy will be started 3 days before the procedure. Patients will be randomly divided into four groups, 50 patients will be disinfected with Bx needle formalin before the procedure, 50 patients will be disinfected with Bx needle povidone iodine before the procedure, 50 patients will be disinfected with Bx needle isopropyl alcohol before the procedure, and the other 50 patients will not be disinfected with isopropyl alcohol, povidone iodine or formalin as in the standard practice. In the first 1 week after the procedure, their symptoms will be questioned by daily phone calls. Within 1 week, complete urinalysis and urine culture will be obtained from symptomatic patients (burning during urination, fever, chills, chills). Patients with a fever above 37.8 will be hospitalized after a complete urine test, urine and blood culture. On day 14, outpatients will be called for outpatient follow-up and patients without any symptoms will be lost to follow-up.
Estimated completion time of the study 6 months Inclusion criteria
- Oriented-coopere patients
- Patients without active urinary tract infection - Patients without active urinary tract infection
- Patients without bleeding diathesis
- Patients who accept the study Exclusion criteria
- Patients with active urinary tract infection
- Patients with bleeding diathesis
- Patients with sonal or cystofix
- Patients with a history of previous prostate surgery Determination of sample size For the main (Primary) hypothesis in our study (The effect of cleaning the biopsy needle with isopropyl alcohol, formalin and povidone iodine before Transrectal Ultrasonography-guided Prostate Biopsy on procedure-related infective complications), power analysis was performed using f-test in independent groups. In order to reach 95% power with α=0.05 error (two-way hypothesis), it was determined that a minimum total of 176 patients were needed as a result of the power analysis calculated using Cohen's d=0.25 effect size calculated by using the literature information. In this study, investigators decided to enroll a total of 200 patients, with a minimum of 50 in each group.
- Conditions
- Prostatic Cancer
- Being tested
- Isopropyl Alcohol, Povidine-iodine, formaldehit, Standard BP control
- Keywords
- Prostatic Neoplasms, Needle washing, Prostate biopsy, Sepsis
- Medical subject headings
- Prostatic Neoplasms, Sepsis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Isopropyl AlcoholDrug
During repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with 70% Isopropyl alcohol every time it came into contact with the rectal mucosa.
Povidine-iodineDrug
During repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with povidine-iodine every time it came into contact with the rectal mucosa.
formaldehitCombination product
During repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with 10% formaldehit every time it came into contact with the rectal mucosa.
Standard BP controlProcedure or surgery
No disinfection method is used in routine use in repetitive procedures when taking a transrectal biopsy.
| Study group | Role | What they receive |
|---|---|---|
| biopsy needle with formalin | Experimental | Not described Receives: Combination Product: formaldehit |
| biopsy needle with povidone iodine | Experimental | Not described Receives: Drug: Povidine-iodine |
| Standart biyopsy | Active comparator | No disinfection method is used in routine use in repetitive procedures when taking a transrectal biopsy. Receives: Procedure: Standard BP control |
| biopsy needle with isopropyl alcohol | Experimental | Not described Receives: Drug: Isopropyl Alcohol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Determination of sample size
For the main (Primary) hypothesis in our study (The effect of cleaning the biopsy needle with isopropyl alcohol, formalin and povidone iodine before Transrectal Ultrasonography-guided Prostate Biopsy on procedure-related infective complications), power analysis was performed using f-test in independent groups. In order to reach 95% power with α=0.05 error (two-way hypothesis), it was determined that a minimum total of 176 patients were needed as a result of the power analysis calculated using Cohen's d=0.25 effect size calculated by using the literature information. In this study, we decided to enroll a total of 200 patients, with a minimum of 50 in each group. Patients will be evaluated with a post-operative survey. Patients will be followed for 4 weeks after the operation.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2025
- Study start1 Mar 2025 (estimated)
- Primary completion30 Apr 2025 (estimated)
- Study completion30 Jun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Prostatic CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hitit University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mustafa Serdar CAGLAYAN, Hitit University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06836271
- Sponsor's protocol ID
- HititUrology001
- Status last verified
- Feb 2025
- First submitted
- 30 Jan 2025
- Last updated
- 20 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Caglayan MS, Kestel M, Ekici M, Aydin C, Ozturk MI, Tasci A, Baykam MM. Effect of needle disinfection with different antiseptic agents on infectious complications after TRUS-guided prostate biopsy: a prospective randomized study. Ther Adv Urol. 2026 Jun 23;18:17562872261458100. doi: 10.1177/17562872261458100. eCollection 2026 Jan-Dec.
PubMed 42369177
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Cleaning the Biopsy Needle With Isopropyl Alcohol, Povidone Iodine and Formalin Before Transrectal Ultrasonography-guided Prostate Biopsy on Procedure-related Infective Complications
- ClinicalTrials.gov ID
- NCT06836271
- Acronym / sponsor ID
- HititUrology001
- Conditions
- Prostatic Cancer
- Keywords
- Prostatic Neoplasms, Needle washing, Prostate biopsy, Sepsis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Hitit UniversityUniversity, hospital or other
- Study start
- 1 Mar 2025 (estimated)
- Primary completion
- 30 Apr 2025 (estimated)
- Study completion
- 30 Jun 2025 (estimated)
- First posted
- 20 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prostate cancer(PCa) is the second most common cancer diagnosed in men. Clinical suspicion of PCa is mentioned in patients with digital rectal examination findings and elevated serum PSA. Despite all the advances in radiological imaging methods, the gold standard method in the diagnosis of the disease is systematic prostate biopsy performed under the guidance of transrectal ultrasonography, which is an invasive procedure.
In TRUS-guided transrectal prostate biopsy, bacteriuria may develop as a result of the rectum flora being injected into the urinary system through a biopsy needle. Infective complications may be encountered as a result of this contamination. Infective complications can present with conditions ranging from asymptomatic bacteriuria to sepsis.
A study has shown that disinfection of the biopsy needle with isopropyl alcohol reduces sepsis due to prostate biopsy compared to the standard procedure. In another study, disinfection of the biopsy needle tip with formalin was found to be associated with a decrease in infectious complications after transrectal prostate biopsy.
In this study, investigators aimed to conduct a prospective study comparing Transrectal Ultrasonography-guided Prostate Biopsy cases, in which the biopsy needle was cleaned with isopropyl alcohol, povidone iodine and formalin, and standard biopsy patients in terms of infectious complications.
Detailed description
Objective To reduce procedure-related infective complications after Transrectal Ultrasonography-guided Prostate Biopsy Method Prostate cancer is the second most common cancer diagnosed in men. In 2020, approximately 1.4 million people were diagnosed worldwide [1,2]. The number of PCa detected by autopsy is roughly the same worldwide [3]. In a systematic review of autopsy studies, the prevalence of PCa under the age of 30 years was reported to be 5% (confidence interval-CI: 95%), with a 1.7 (1.6-1.8) (odds ratio-OR) fold increase per 10 years, reaching 59% (48-71%) over the age of 79 years [4].
Clinical suspicion of PCa is mentioned in patients with finger rectal examination findings and elevated serum PSA. Despite all the advances in radiologic imaging modalities, the gold standard method for the diagnosis of the disease is systematic prostate biopsy under transrectal ultrasonography guidance, which is an invasive procedure. [5]
Transrectal ultrasonography (TRUS) was first described by Wild and Reid in 1957. TRUS plays an important role in prostate diseases as it is inexpensive, easily applicable and guides biopsy. Conventional TRUS-guided prostate biopsy is performed with 12 pieces of tru-cut samples taken systematically and randomized.
Although it can be safely performed in the outpatient setting and is easily tolerated by patients, Transrectal Ultrasonography-guided Prostate Biopsy can lead to serious complications such as hematuria, rectal bleeding, acute urinary retention, urinary tract infection and sepsis.
Urinary tract infection accompanied by fever is the most common complication after biopsy. Bacteriuria after prostate biopsy is reported between 20% and 50% in the literature. [6] Several studies have shown that antibiotic prophylaxis largely prevents infection. [6,7]
During TRUS-guided transrectal prostate biopsy, bacteriuria may develop as a result of the rectal flora being introduced into the urinary system through the biopsy needle. Infective complications may occur as a result of this transmission. Infective complications can range from asymptomatic bacteriuria to sepsis.
In one study, disinfection of the biopsy needle with isopropyl alcohol was shown to reduce prostate biopsy-related sepsis compared to the standard procedure. [8] In another study, disinfection of the biopsy needle tip with formalin was associated with a decrease in infectious complications after transrectal prostate biopsy.[9] In this study, investigators aimed to prospectively examine the infectious complications occurring in a total of 200 cases of Transrectal Ultrasonography-guided Prostate Biopsy to be performed in our clinic in 2025.
In 200 patients who underwent Trans Rectal Ultrasonography-guided prostate biopsy procedure, infective parameters, signs and symptoms such as fever, dysuria, and possible complications such as hospitalization requirement, sepsis will be prospectively investigated to evaluate postop infective complications of disinfection of the biopsy needle with formalin, povidone iodine or isopropyl alcohol before each biopsy.
In the study, each patient will undergo bt-enema for bowel cleansing before the procedure, rectal cleansing with povidone iodine, and prophylactic antibiotherapy will be started 3 days before the procedure. Patients will be randomly divided into four groups, 50 patients will be disinfected with Bx needle formalin before the procedure, 50 patients will be disinfected with Bx needle povidone iodine before the procedure, 50 patients will be disinfected with Bx needle isopropyl alcohol before the procedure, and the other 50 patients will not be disinfected with isopropyl alcohol, povidone iodine or formalin as in the standard practice. In the first 1 week after the procedure, their symptoms will be questioned by daily phone calls. Within 1 week, complete urinalysis and urine culture will be obtained from symptomatic patients (burning during urination, fever, chills, chills). Patients with a fever above 37.8 will be hospitalized after a complete urine test, urine and blood culture. On day 14, outpatients will be called for outpatient follow-up and patients without any symptoms will be lost to follow-up.
Estimated completion time of the study 6 months Inclusion criteria
- Oriented-coopere patients
- Patients without active urinary tract infection - Patients without active urinary tract infection
- Patients without bleeding diathesis
- Patients who accept the study Exclusion criteria
- Patients with active urinary tract infection
- Patients with bleeding diathesis
- Patients with sonal or cystofix
- Patients with a history of previous prostate surgery Determination of sample size For the main (Primary) hypothesis in our study (The effect of cleaning the biopsy needle with isopropyl alcohol, formalin and povidone iodine before Transrectal Ultrasonography-guided Prostate Biopsy on procedure-related infective complications), power analysis was performed using f-test in independent groups. In order to reach 95% power with α=0.05 error (two-way hypothesis), it was determined that a minimum total of 176 patients were needed as a result of the power analysis calculated using Cohen's d=0.25 effect size calculated by using the literature information. In this study, investigators decided to enroll a total of 200 patients, with a minimum of 50 in each group.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| biopsy needle with formalin | Experimental | Combination Product: formaldehit |
| biopsy needle with povidone iodine | Experimental | Drug: Povidine-iodine |
| Standart biyopsy | Active comparator | Procedure: Standard BP controlNo disinfection method is used in routine use in repetitive procedures when taking a transrectal biopsy. |
| biopsy needle with isopropyl alcohol | Experimental | Drug: Isopropyl Alcohol |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Oriented-coopere patients
- Patients without active urinary tract infection - Patients without active urinary tract infection
- Patients without bleeding diathesis
- Patients who accept the study
Key exclusion criteria (4 listed)
- Patients with active urinary tract infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Isopropyl AlcoholDuring repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with 70% Isopropyl alcohol every time it came into contact with the rectal mucosa. | Drug | biopsy needle with isopropyl alcohol |
| Povidine-iodineDuring repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with povidine-iodine every time it came into contact with the rectal mucosa. | Drug | biopsy needle with povidone iodine |
| formaldehitDuring repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with 10% formaldehit every time it came into contact with the rectal mucosa. | Combination product | biopsy needle with formalin |
| Standard BP controlNo disinfection method is used in routine use in repetitive procedures when taking a transrectal biopsy. | Procedure or surgery | Standart biyopsy |
Primary outcome
Determination of sample size
Time frame: 6 months
For the main (Primary) hypothesis in our study (The effect of cleaning the biopsy needle with isopropyl alcohol, formalin and povidone iodine before Transrectal Ultrasonography-guided Prostate Biopsy on procedure-related infective complications), power analysis was performed using f-test in independent groups. In order to reach 95% power with α=0.05 error (two-way hypothesis), it was determined that a minimum total of 176 patients were needed as a result of the power analysis calculated using Cohen's d=0.25 effect size calculated by using the literature information. In this study, we decided to enroll a total of 200 patients, with a minimum of 50 in each group. Patients will be evaluated with a post-operative survey. Patients will be followed for 4 weeks after the operation.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2025.
- Derived from this study: PubMed 42369177Caglayan MS, Kestel M, Ekici M, Aydin C, Ozturk MI, Tasci A, Baykam MM. Effect of needle disinfection with different antiseptic agents on infectious complications after TRUS-guided prostate biopsy: a prospective randomized study. Ther Adv Urol. 2026 Jun 23;18:17562872261458100. doi: 10.1177/17562872261458100. eCollection 2026 Jan-Dec.
Related trials for Prostatic Cancer
RecruitingPhase 2
The COSMYC Trial (COmbined Suppression of MYC)
Metastatic Castration-resistant Prostate Cancer
Not yet recruitingPhase 3
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
Prostatic Neoplasms
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingObservational study
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Metastatic Prostate Cancer
RecruitingPhase 2
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Prostate Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Isopropyl Alcohol, Povidine-iodine and formaldehit in people with Prostatic Cancer, run by Hitit University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mustafa S CAGLAYAN (905074311951, serdar.09.09@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determination of sample size (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06836271, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2025.